XML 29 R16.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTARY INFORMATION
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION
Sundry Income (Expense) - Net
(In millions) For the years ended December 31,202420232022
Non-operating pension and other post-employment benefit ("OPEB") credits (costs)$18 $(9)$28 
Interest income 1, 2
73 155 50 
Net gain on divestiture and sales of other assets and investments 3, 4, 5
20 19 78 
Foreign exchange gains (losses), net3 (73)15 
Loss on debt extinguishment 6
(74)— — 
Interest rate swap mark-to-market loss 7
(138)— — 
Miscellaneous income (expenses) - net22 10 20 
Sundry income (expense) - net$(76)$102 $191 
1.The years ended December 31, 2024 and 2023 include non-cash interest income of $26 million and $4 million, respectively, related to the $350 million Delrin® related party note receivable. Refer to Note 4 for additional information.
2.The year ended December 31, 2023 includes interest on cash and marketable securities. Fluctuations in interest income are due to changes in cash balances and/or changes in interest rates.
3.The year ended December 31, 2024 primarily reflects income related to gains on sale of intellectual property.
4.The year ended December 31, 2023 primarily reflects income related to a land sale within the IndustrialsCo segment and gain adjustments from previously divested businesses.
5.The year ended December 31, 2022 primarily reflects income of $26 million related to the gain on sale of the Biomaterials business unit and income of $37 million related to the sale of a land use right within the IndustrialsCo segment.
6.Reflects the loss on the partial redemption of an aggregate principal amount of the 2038 Notes. Refer to Note 15 for further details.
7.Includes the mark-to-market loss related to the 2022 Swaps and 2024 Swaps. Refer to Note 21 for further details.

Cash, Cash Equivalents and Restricted Cash
At December 31, 2024 and 2023, the Company had restricted cash of $6 million and $411 million, respectively, within “Restricted cash and cash equivalents” in the Consolidated Balance Sheets. At December 31, 2024, the Company also had $36 million, within "Restricted cash and cash equivalents - noncurrent", which is related to the MOU escrow account deposits. During the second quarter 2024, the judgment related to the Water District Settlement Fund became final and therefore $408 million was removed from "Restricted cash and cash equivalents”. Additional information can be found in Note 16.

Accrued and Other Current Liabilities
"Accrued and other current liabilities" in the Consolidated Balance Sheets were $1,031 million at December 31, 2024 and $1,269 million at December 31, 2023. "Accrued and other current liabilities" at December 31, 2023 includes approximately $405 million related to a settlement agreement further discussed in Note 16. Accrued payroll, which is a component of "Accrued and other current liabilities" was $383 million at December 31, 2024 and $250 million at December 31, 2023. No other component of "Accrued and other current liabilities" was more than five percent of total current liabilities at December 31, 2024 and 2023.